JETEMA, Co., Ltd. (216080.KQ)
KRW 15130.0
(-2.64%)
KRW 15130.0
(-2.64%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 84.27 Billion KRW | -2.61% |
| 2022 | 86.53 Billion KRW | 585.62% |
| 2021 | -17.81 Billion KRW | -1451.33% |
| 2020 | -1.14 Billion KRW | -108.08% |
| 2019 | 14.22 Billion KRW | -32.54% |
| 2018 | 21.07 Billion KRW | 81.84% |
| 2017 | 11.59 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 89.29 Billion KRW | 3.08% |
| 2024 Q1 | 85.98 Billion KRW | 2.03% |
| 2023 Q1 | 90.69 Billion KRW | 4.81% |
| 2023 FY | 84.27 Billion KRW | -2.61% |
| 2023 Q4 | 84.27 Billion KRW | 15.78% |
| 2023 Q3 | 72.79 Billion KRW | -20.66% |
| 2023 Q2 | 91.75 Billion KRW | 1.17% |
| 2022 Q4 | 86.53 Billion KRW | 12.92% |
| 2022 Q3 | 76.63 Billion KRW | -2.6% |
| 2022 Q2 | 78.68 Billion KRW | 708.91% |
| 2022 Q1 | -12.92 Billion KRW | 27.49% |
| 2022 FY | 86.53 Billion KRW | 585.62% |
| 2021 Q2 | 5.28 Billion KRW | 470.13% |
| 2021 Q4 | -17.81 Billion KRW | -0.45% |
| 2021 FY | -17.81 Billion KRW | -1451.33% |
| 2021 Q1 | -1.42 Billion KRW | 91.57% |
| 2021 Q3 | -17.74 Billion KRW | -435.8% |
| 2020 Q1 | -5.47 Billion KRW | -80.75% |
| 2020 FY | -1.14 Billion KRW | -108.08% |
| 2020 Q3 | -12.63 Billion KRW | -29.63% |
| 2020 Q4 | -16.94 Billion KRW | -34.05% |
| 2020 Q2 | -9.74 Billion KRW | -77.99% |
| 2019 Q4 | -3.03 Billion KRW | -136.19% |
| 2019 FY | 14.22 Billion KRW | -32.54% |
| 2019 Q3 | 8.37 Billion KRW | 0.0% |
| 2019 Q1 | 14.01 Billion KRW | 0.0% |
| 2018 Q1 | 1.86 Billion KRW | 0.0% |
| 2018 FY | 21.07 Billion KRW | 81.84% |
| 2017 FY | 11.59 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 282.489% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 307.662% |
| BINEX Co., Ltd. | 45.34 Billion KRW | -85.852% |
| Bioneer Corporation | -3.9 Billion KRW | 2256.7% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | -909.117% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | -468.904% |
| CrystalGenomics, Inc. | 8.99 Billion USD | -837.28% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 445.042% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 78.331% |
| Medy-Tox Inc. | 49.58 Billion KRW | -69.972% |
| Peptron, Inc. | 4.86 Billion KRW | -1631.068% |
| Amicogen, Inc. | 125.26 Billion KRW | 32.718% |
| Genexine, Inc. | 61.39 Billion KRW | -37.272% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | 715.772% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 250.355% |
| ALTEOGEN Inc. | 53.56 Billion KRW | -57.326% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 355.869% |
| SillaJen, Inc. | -13.89 Billion KRW | 706.693% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | -207.872% |
| Genomictree Inc. | -43.43 Billion KRW | 294.035% |
| MedPacto, Inc. | -64 Billion KRW | 231.685% |
| D&D Pharmatech | -7.5 Billion KRW | 1222.556% |
| EASY BIO,Inc. | 53.21 Billion KRW | -58.388% |
| GI Innovation, Inc. | -4.82 Billion KRW | 1847.624% |